A Phase 1/2 interventional study of Clarithromycin and Dexamethasone in Myeloma, sponsored by Joseph Tuscano. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Joseph Tuscano · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 502 studies in Neoplasms, Plasma Cell with a site in United States — 26 open to participants now, 43 under way, 2 of them phase 3. Neoplasms, Plasma Cell · United States.
Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, this one is the 195th largest by enrollment of the 386 interventional ones that give a count, is one of 8 that started in 2015, is one of 57 in phase 1/2, and was the 418th registered.
710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.
Browse Neoplasms, Plasma Cell studies →26 of the 502 studies in Neoplasms, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 40–49 · Healthy volunteers
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
502 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 185 · Phase 2 252 · Phase 3 41 · Phase 4 4
First in 1975; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 40 across 527 interventional studies indexed under Neoplasms, Plasma Cell.
Median enrollment 33 across the 386 interventional studies, 159 across the 42 observational. Of the 430 that completed or were terminated, 152 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 502 have an industry lead sponsor. The 10 most frequent:
Joseph Tuscano is the lead sponsor of 5 studies on the registry; none are open to participants now.
Joseph Tuscano has 1 study filed under Neoplasms, Plasma Cell — fewer than ten, so there is no comparison to draw.
13 of the studies in Neoplasms, Plasma Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT01269593Memorial Sloan Kettering Cancer CenterPET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study | 2026-12 |
| NCT05336383M.D. Anderson Cancer CenterPhase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | 2026-12-07 |
| NCT06271252OriCell Therapeutics Co., Ltd.A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | 2026-12-12 |
| NCT07052916Memorial Sloan Kettering Cancer CenterA Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties | 2026-12-27 |
Add all 13 to your calendar (.ics) → With an account.
Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase I/II trial studies the side effects and best dose of clarithromycin when given together with ixazomib citrate, pomalidomide, and dexamethasone and to see how well it works in treating patients with multiple myeloma that has not responded to previous treatment. Biological therapies, such as clarithromycin, pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving clarithromycin with ixazomib citrate, pomalidomide and dexamethasone may be a better treatment for patients with multiple myeloma.
PRIMARY OBJECTIVES:
I. To establish the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) for PiC-D therapy (pomalidomide, ixazomib [ixazomib citrate], clarithromycin, and dexamethasone) in patients with multiple myeloma who are bortezomib and lenalidomide refractory. (Phase I) II. To determine the complete response (CR) and stringent CR (sCR) rate for PiC-D therapy in patients with multiple myeloma who are bortezomib and lenalidomide refractory. (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of PiC-D therapy. (Phase I) II. To characterize the pharmacokinetics (PK) in plasma of oral ixazomib in combination with pomalidomide, clarithromycin and dexamethasone. (Phase I) III. To assess preliminary evidence of clinical activity. (Phase I) IV. To assess the effects of PiC-D therapy on quality of life (QOL). (Phase I)
VI. To evaluate the safety of PiC-D therapy. (Phase II) VII. To determine the overall response rate (ORR) (ORR; CR, sCR, partial response, and very good partial response. (Phase II) VIII. To determine the clinical benefit rate (CBR) (CBR; minimal response + ORR). (Phase II) IX. To determine the disease control rate (DCR) (DCR; stable disease + CBR). (Phase II) X. To determine the duration of response (DOR) in patients achieving a partial response or better. (Phase II) XI. To determine the time to next treatment (TNT). (Phase II) XII. To determine progression free survival (PFS) and overall survival (OS). (Phase II)
OUTLINE: This is a phase I, dose-escalation study of clarithromycin followed by a phase II study.
Patients receive pomalidomide orally (PO) once daily (QD) on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO twice daily (BID) on days 15-21 of course 1 and days 1-21 and courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY:
Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 2-3 months for up to 3 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have according to International Myeloma Working Group (IMWG) criteria; measurable disease includes at least one of the following criteria:
Disease that has progressed during or within 6 months of coming off therapy with bortezomib and lenalidomide (either sequentially or concurrent); progressive disease is defined as any of the following:
An increase of >= 25% from lowest response value in any of the following:
Female patients who:
Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:
Exclusion Criteria:
Systemic treatment within 14 days before the first dose of study drugs, or concurrent use, with any of the following:
Patients with (HIV) infection may be eligible provided they meet the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive pomalidomide PO QD on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO BID on days 15-21 of course 1 and days 1-21 of courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Clarithromycin · Drug: Dexamethasone · Drug: Ixazomib Citrate · Drug: Pomalidomide
Given PO
Also known as: Biaxin
Given PO
Also known as: Decadron
Given PO
Also known as: MLN9708
Given PO
Also known as: Pomalyst
Maximum Tolerated Dose (MTD) (Phase I)
The MTD is defined as the highest dose tested in which fewer than 33% of patients experience a dose limiting toxicity and at least 6 patients have been treated at that dose. The MTD will be the recommended Phase 2 dose, provided that other safety considerations are acceptable. Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time frame: About 14 months.
Complete Response (CR) and Stringent CR (Phase 2)
Defined by the International Myeloma Working Group (IMWG) criteria. omplete response (CR) = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow. Stringent complete response (sCR) = CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\>
Time frame: Up to about 7 years
Safety and Tolerability of PiC-D Therapy (Phase 1)
Proportion of patients experiencing dose limiting toxciity (DLT).
Time frame: Up to about 14 months
Preliminary Evidence of Clinical Activity (Phase 1).
SD (stable disease), VGPR (very good partial response), sCR (stringent complete response), overall response rate (ORR), CBR (clinical benefit rate), and DCR (disease control rate).
Time frame: Up to 3 years
Quality of Life (Phase 1)
Cancer Therapy Satisfaction Questionnaire and EORTC QLQ-MY20 score.
Time frame: Up to 2 years
Safety (Phase 2)
Proportion of patients experiencing treatment-emergent adverse events, graded according to CTCAE v4.03.
Time frame: Up to about 2.5 years
Overall Response Rate (ORR) (Phase 2)
ORR = PR+VGPR+CR. Overall response rate (ORR) includes Partial Response (PR) + Very Good Partial Response (VGPR) + Complete Response (CR). Response will be assessed per the International Myeloma Working Group (IMWG) Response Criteria
Time frame: Up to about 7 years
Clinical Benefit Rate (CBR) (Phase 2)
CBR = Number of participants with Minimal Response (MR) or better, defined as sCR (Stringent Complete Response) + CR (Complete Response) + VGPR (Very Good Partial Response) + PR (Partial Response) + MR (Minimal Response).
Time frame: Up to 3 years
Disease Control Rate (DCR) (Phase 2)
Disease control rate (DCR) = stable disease (SD) + overall response rate (ORR)
Time frame: Up to about 7 years
Duration of Response (DOR) (Phase 2)
DOR = Partial response (PR) or better. PR defined per IMWG as ≥ 50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥ 90% or to \< 200 smg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥ 50% reduction in plasma cells is required in place of the M-protein, provided baseline bone marrow plasma cell percentage was ≥ 30% In addition to the above listed criteria, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.
Time frame: Up to about 7 years
Progression Free Survival (PFS) (Phase 2)
Median progression free survival (PFS) - Median time from initiation of study intervention to progressive disease (PD) per IMWG criteria.
Time frame: Up to 3 years
Overall Survival (OS) (Phase 2)
Median time from initiation of study intervention to death from any cause
Time frame: Up to about 6 years
Quality of Life (QoL) (Phase 2)
Cancer Therapy Satisfaction Questionnaire (CTSQ-16) - Perceived worth of therapy, taken at screening and at end of treatment.
Time frame: Baseline and end of treatment (up to 3 years).
Phamacokinetic Parameters of Ixazomib Citrate
Data not collected
Time frame: at 0.5, 1, 1.5, 2, 4, 8, and 24 hours after ixazomib citrate administration on days 1 and 8.
| Milestone | Phase 1: Dose Level 1 | Phase 1: Dose Level -1 | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|---|---|
| Started | 6 | 0 | 26 |
| Completed | 6 | 0 | 26 |
| Not completed | 0 | 0 | 0 |
The MTD is defined as the highest dose tested in which fewer than 33% of patients experience a dose limiting toxicity and at least 6 patients have been treated at that dose. The MTD will be the recommended Phase 2 dose, provided that other safety considerations are acceptable. Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
| mg | Phase 1: Treatment (PiC-D Therapy) Dose Escalation |
|---|---|
| Maximum Tolerated Dose (MTD) (Phase I) | 250 |
Defined by the International Myeloma Working Group (IMWG) criteria. omplete response (CR) = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow. Stringent complete response (sCR) = CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\>
| Participants | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|
| Complete Response (CR) and Stringent CR (Phase 2) | 6 |
Proportion of patients experiencing dose limiting toxciity (DLT).
| Participants | Phase 1: Treatment (PiC-D Therapy) Dose Escalation |
|---|---|
| Safety and Tolerability of PiC-D Therapy (Phase 1) | 1 |
SD (stable disease), VGPR (very good partial response), sCR (stringent complete response), overall response rate (ORR), CBR (clinical benefit rate), and DCR (disease control rate).
| participants | Phase 1: Treatment (PiC-D Therapy) Dose Escalation |
|---|---|
| SD | 2 |
| VGPR | 2 |
| sCR | 1 |
| ORR | 3 |
| CBR | 3 |
| DCR | 5 |
Cancer Therapy Satisfaction Questionnaire and EORTC QLQ-MY20 score.
Results for this outcome have not been posted.
Proportion of patients experiencing treatment-emergent adverse events, graded according to CTCAE v4.03.
| Participants | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|
| Safety (Phase 2) | 28 |
ORR = PR+VGPR+CR. Overall response rate (ORR) includes Partial Response (PR) + Very Good Partial Response (VGPR) + Complete Response (CR). Response will be assessed per the International Myeloma Working Group (IMWG) Response Criteria
| participants | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|
| Overall Response Rate (ORR) (Phase 2) | 21 |
CBR = Number of participants with Minimal Response (MR) or better, defined as sCR (Stringent Complete Response) + CR (Complete Response) + VGPR (Very Good Partial Response) + PR (Partial Response) + MR (Minimal Response).
| participants | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|
| Clinical Benefit Rate (CBR) (Phase 2) | 21 |
Disease control rate (DCR) = stable disease (SD) + overall response rate (ORR)
| Participants | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|
| Disease Control Rate (DCR) (Phase 2) | 28 |
DOR = Partial response (PR) or better. PR defined per IMWG as ≥ 50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥ 90% or to \< 200 smg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥ 50% reduction in plasma cells is required in place of the M-protein, provided baseline bone marrow plasma cell percentage was ≥ 30% In addition to the above listed criteria, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.
| months | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|
| Duration of Response (DOR) (Phase 2) | 19.8 (12.4 to NA) |
Median progression free survival (PFS) - Median time from initiation of study intervention to progressive disease (PD) per IMWG criteria.
| months | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|
| Progression Free Survival (PFS) (Phase 2) | 22.2 (13.3 to NA) |
Median time from initiation of study intervention to death from any cause
| months | Phase 2: Treatment (PiC-D Therapy) MTD Expansion |
|---|---|
| Overall Survival (OS) (Phase 2) | NA (22.1 to NA) |
Cancer Therapy Satisfaction Questionnaire (CTSQ-16) - Perceived worth of therapy, taken at screening and at end of treatment.
| percentage of participants | QoL Item: Worth Taking Even With Side Effects, Screening | QoL Iiem: Worth Taking Even With Side Effects, End of Treatment | QoL Item: Overall Worthwhileness - Screening | QoL Item: Overall Worthwhileness - End of Treatment |
|---|---|---|---|---|
| Never | 6.2 | 0 | 5.9 | 0 |
| Rarely | 6 | 0 | 0 | 16.7 |
| Sometimes | 12.5 | 33.3 | 11.8 | 50.0 |
| Most of the Time | 12.5 | 33.3 | 29.4 | 0 |
| Always | 62.5 | 33.3 | 52.9 | 33.3 |
Data not collected
No measurements were reported for this outcome.
Collected over From date of first study treatment until date of off treatment: up to 2.5 years for serious adverse events and other (not including serious) adverse events; and up to about 7 years for all-cause mortality.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment (PiC-D Therapy) | 0/32 (0%) | 6/32 (18.8%) | 32/32 (100%) |
| Event | Treatment (PiC-D Therapy) |
|---|---|
| Cerebrovascular AccidentVascular disorders | 1/32 |
| Colonic perforationGastrointestinal disorders | 1/32 |
| InfluenzaInfections and infestations | 1/32 |
| Neoplasm, other-disease progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/32 |
| OsteomyelitisEar and labyrinth disorders | 1/32 |
| Upper GI hemorrhageGastrointestinal disorders | 1/32 |
| Event | Treatment (PiC-D Therapy) |
|---|---|
| FatigueGeneral disorders | 20/32 |
| ConstipationGastrointestinal disorders | 15/32 |
| NauseaGastrointestinal disorders | 14/32 |
| InsomniaPsychiatric disorders | 12/32 |
| DiarrheaGastrointestinal disorders | 10/32 |
| HypertensionVascular disorders | 10/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/32 |
| PainGeneral disorders | 9/32 |
| Upper respiratory infectionInfections and infestations | 9/32 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 8/32 |
| Age, Categorical(Participants) | Phase 1: Treatment (PiC-D Therapy) Dose Escalation | Phase 2: Treatment (PiC-D Therapy) MTD Expansion | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 6 | 7 |
| >=65 years | 5 | 20 | 25 |
| Sex: Female, Male(Participants) | Phase 1: Treatment (PiC-D Therapy) Dose Escalation | Phase 2: Treatment (PiC-D Therapy) MTD Expansion | Total |
|---|---|---|---|
| Female | 3 | 7 | 10 |
| Male | 3 | 19 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Treatment (PiC-D Therapy) Dose Escalation | Phase 2: Treatment (PiC-D Therapy) MTD Expansion | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 6 |
| Not Hispanic or Latino | 4 | 22 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Phase 1: Treatment (PiC-D Therapy) Dose Escalation | Phase 2: Treatment (PiC-D Therapy) MTD Expansion | Total |
|---|---|---|---|
| United States | 6 | 26 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Dec 2022, 85 months.
Results were first posted in Nov 2026, 3 years 10 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2025 → Dec 2022 and completion Dec 2025 → Nov 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixazomib
Joseph Tuscano